title: Varicella vaccine.
abstract: Varicella vaccine is safe, effective, and cost-effective in healthy children, adolescents, and adults. Breakthrough cases of MVLS are significantly milder than wild-type varicella infection. No severe adverse events have been reported following vaccination, and the incidence of herpes zoster is less in vaccinees than in individuals who have had natural varicella infections. To date, there is no evidence waning immunity following vaccination. "New and improved" varicella vaccines that may be more effective than the current vaccine and can be stored at refrigerator temperatures may soon become available in the United States.
authors.affiliation: Department of Pediatrics, Creighton University, Omaha, Nebraska, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Chartrand
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D044466:Asian People; D002644:Chickenpox / Q000150:complications / Q000276:immunology; D019433:Chickenpox Vaccine / Q000009:adverse effects / Q000145:classification / Q000276:immunology; D002648:Child; D014645:Herpesvirus 3, Human / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D007156:Immunologic Memory; D007564:Japan
chemical_list: D019433:Chickenpox Vaccine